Patents Assigned to Janssen Biologics B.V.
  • Manufacturing methods to control C-terminal lysine, galactose and sialic acid content in recombinant proteins
    Patent number: 11149085
    Abstract: Provided herein is a method for producing an antibody, such as an anti-TNF? antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 ?M zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: October 19, 2021
    Assignees: JANSSEN BIOTECH, INC., JANSSEN BIOLOGICS B.V.
    Inventors: Marcel Flikweert, Charles Goochee, Francis C. Maslanka, Franciscus Johannes Ignatius Nagel, James R. Ryland, Eugene Schaefer
  • MANUFACTURING METHODS TO CONTROL C-TERMINAL LYSINE, GALACTOSE AND SIALIC ACID CONTENT IN RECOMBINANT PROTEINS
    Publication number: 20140273092
    Abstract: Provided herein is a method for producing an antibody, such as an anti-TNF? antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 ?M zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicants: Janssen Biologics B.V., Janssen Biotech, Inc.
    Inventors: Marcel Flikweert, Charles Goochee, Francis Maslanka, Franciscus Johannes Ignatius Nagel, James Ryland, Eugene Schaefer